A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients FINE Trial

Akman Demir, Gulsen; Turkoglu, Recai; Saip, Sabahattin; Yuceyar, Nur; EFENDİ, HÜSNÜ; TURAN, ÖMER; AĞAN YILDIRIM, KADRİYE; TERZİ, MURAT; BOZ, CAVİT; Tuncer, Asli; Kocer, Belgin; Kasap, Mithat; Caliskan, Zeynep

doi:10.5152/npa.2017.20515

A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients FINE Trial

Atıf İçin Kopyala

Akman Demir G., Turkoglu R., Saip S., Yuceyar N., EFENDİ H. , TURAN Ö. F. , ...Daha Fazla

NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, cilt.56, ss.253-257, 2019 (SCI İndekslerine Giren Dergi)

Cilt numarası: 56 Konu: 4
Basım Tarihi: 2019
Doi Numarası: 10.5152/npa.2017.20515
Dergi Adı: NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY
Sayfa Sayıları: ss.253-257

Özet

Introduction: To assess satisfaction and quality of life in patients with relapsing-remitting multiple sclerosis (RRMS) who were receiving fingolimod (0.5 mg/day) for 12 months as a second-line treatment after switching from injectable agents.